Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):167-74. doi: 10.1016/j.ijrobp.2014.01.040. Epub 2014 Mar 7.
To assess whether an increase in a subvolume of intrahepatic tumor with elevated arterial perfusion during radiation therapy (RT) predicts tumor progression after RT.
Twenty patients with unresectable intrahepatic cancers undergoing RT were enrolled in a prospective, institutional review board-approved study. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed before RT (pre-RT), after delivering ∼60% of the planned dose (mid-RT) and 1 month after completion of RT to quantify hepatic arterial perfusion. The arterial perfusions of the tumors at pre-RT were clustered into low-normal and elevated perfusion by a fuzzy clustering-based method, and the tumor subvolumes with elevated arterial perfusion were extracted from the hepatic arterial perfusion images. The percentage changes in the tumor subvolumes and means of arterial perfusion over the tumors from pre-RT to mid-RT were evaluated for predicting tumor progression post-RT.
Of the 24 tumors, 6 tumors in 5 patients progressed 5 to 21 months after RT completion. Neither tumor volumes nor means of tumor arterial perfusion at pre-RT were predictive of treatment outcome. The mean arterial perfusion over the tumors increased significantly at mid-RT in progressive tumors compared with the responsive tumors (P=.006). From pre-RT to mid-RT, the responsive tumors had a decrease in the tumor subvolumes with elevated arterial perfusion (median, -14%; range, -75% to 65%), whereas the progressive tumors had an increase of the subvolumes (median, 57%; range, -7% to 165%) (P=.003). Receiver operating characteristic analysis of the percentage change in the subvolume for predicting tumor progression post-RT had an area under the curve of 0.90.
The increase in the subvolume of the intrahepatic tumor with elevated arterial perfusion during RT has the potential to be a predictor for tumor progression post-RT. The tumor subvolume could be a radiation boost candidate for response-driven adaptive RT.
评估放疗期间肝内肿瘤局部亚体积动脉灌注增加是否能预测放疗后肿瘤进展。
20 例接受放疗的不可切除肝内癌症患者参与了一项前瞻性、机构审查委员会批准的研究。在放疗前(放疗前)、计划剂量完成约 60%时(中放疗)和放疗完成后 1 个月进行动态对比增强磁共振成像(DCE-MRI),以量化肝动脉灌注。采用基于模糊聚类的方法将放疗前肿瘤的动脉灌注分为低正常和升高灌注,并从肝动脉灌注图像中提取动脉灌注升高的肿瘤亚体积。从放疗前到中放疗,评估肿瘤亚体积和肿瘤动脉灌注均值的变化,以预测放疗后肿瘤进展。
在 24 个肿瘤中,5 例患者的 6 个肿瘤在放疗后 5 至 21 个月进展。肿瘤体积和放疗前肿瘤动脉灌注均值均不能预测治疗结果。与反应性肿瘤相比,进展性肿瘤的肿瘤动脉灌注均值在中放疗时显著增加(P=.006)。从放疗前到中放疗,反应性肿瘤的动脉灌注升高的肿瘤亚体积减少(中位数,-14%;范围,-75%至 65%),而进展性肿瘤的亚体积增加(中位数,57%;范围,-7%至 165%)(P=.003)。预测放疗后肿瘤进展的亚体积百分比变化的受试者工作特征曲线分析的曲线下面积为 0.90。
放疗期间肝内肿瘤局部亚体积动脉灌注增加有可能成为放疗后肿瘤进展的预测指标。肿瘤亚体积可能是反应驱动适应性放疗的放射增敏候选部位。